These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36520468)

  • 1. Lulla PD. CAR T cells and autologous transplantation can coexist for DLBCL. Blood. 2021;139(9):1266-1267.
    Blood; 2022 Dec; 140(24):2646. PubMed ID: 36520468
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response.
    Akhtar OS; Cao B; Wang X; Torka P; Al-Jumayli M; Locke FL; Freeman CL
    Blood Adv; 2023 Oct; 7(19):5937-5940. PubMed ID: 37236167
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
    Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
    Kochenderfer JN; Somerville RPT; Lu T; Yang JC; Sherry RM; Feldman SA; McIntyre L; Bot A; Rossi J; Lam N; Rosenberg SA
    Mol Ther; 2017 Oct; 25(10):2245-2253. PubMed ID: 28803861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR T cells and autologous transplantation can coexist for DLBCL.
    Lulla PD
    Blood; 2022 Mar; 139(9):1266-1267. PubMed ID: 35238887
    [No Abstract]   [Full Text] [Related]  

  • 7. CD19 CAR T-cell infusion during severe COVID-19 acute respiratory distress syndrome in large B-cell lymphoma.
    Buchtele N; Wohlfarth P; Staudinger T; Schellongowski P; Traby L; Vossen M; Knaus H; Lobmeyr E; Rabitsch W; Worel N; Staber PB
    Ann Hematol; 2023 Jan; 102(1):231-234. PubMed ID: 36399193
    [No Abstract]   [Full Text] [Related]  

  • 8. Now you see me, now you don't: Isolated central nervous system recurrence of CD19-negative diffuse large B-cell lymphoma following CD19-directed CAR T-cell treatment.
    Gokozan HN; Ouseph MM; Carniello JVS; Besien KV; Patel SS
    Cytopathology; 2022 Nov; 33(6):757-759. PubMed ID: 35713946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary outcomes reported from three randomized controlled trials of CD19 CAR-T cell therapies in large B cell lymphoma.
    Jain MD
    Mol Ther; 2022 Jan; 30(1):14-16. PubMed ID: 34921770
    [No Abstract]   [Full Text] [Related]  

  • 11. Unresolved questions in the second-line use of CAR-T cells for diffuse large B cell lymphoma.
    Cliff ERS; Merryman RW; Armand P; Jacobson CA
    Nat Med; 2022 Dec; 28(12):2458-2459. PubMed ID: 36348063
    [No Abstract]   [Full Text] [Related]  

  • 12. Late Events After CD-19 CAR-T Treatment.
    Hossain NM; Nishimura MI
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
    [No Abstract]   [Full Text] [Related]  

  • 13. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
    Jeyakumar N; Smith M
    Front Immunol; 2022; 13():887866. PubMed ID: 35663947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to perform leukapheresis for procurement of the staring material used for commercial CAR T-cell manufacturing: A consensus from experts convened by the SFGM-TC].
    Carnoy S; Beaumont JL; Kanouni T; Parquet N; Beauvais D; Hequet O; Kanold J; Ballot C; Mialou V; Reppel L; Damaj G; Yakoub-Agha I; Chabannon C
    Bull Cancer; 2021 Mar; 108(3):295-303. PubMed ID: 33610284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real world CAR T cell data in diffuse large B-cell lymphoma: hitting a moving target.
    Yamshon S; Jing-Mei H
    Leuk Lymphoma; 2022 Sep; 63(9):2019-2020. PubMed ID: 35821624
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
    Dreger P; Holtick U; Subklewe M; von Tresckow B; Ayuk F; Wagner E; Wulf G; Marks R; Penack O; Schnetzke U; Koenecke C; von Bonin M; Stelljes M; Glass B; Baldus CD; Vucinic V; Mougiakakos D; Topp M; Schroers R; Wolff D; Thomas S; Kröger N; Bethge WA; ;
    Bone Marrow Transplant; 2023 Feb; 58(2):229-232. PubMed ID: 36418916
    [No Abstract]   [Full Text] [Related]  

  • 17. Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Galli E; Sorà F; Hohaus S; Bellesi S; Autore F; Metafuni E; Innocenti I; Marra J; Fresa A; Limongiello MA; Giammarco S; Leccisotti L; Guarneri A; Chiusolo P; Laurenti L; Teofili L; Piccirillo N; Bacigalupo A; Sica S
    Bone Marrow Transplant; 2022 May; 57(5):837-839. PubMed ID: 35260803
    [No Abstract]   [Full Text] [Related]  

  • 18. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
    Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
    Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma.
    Wei J; Zhu X; Mao X; Huang L; Meng F; Zhou J
    J Immunother Cancer; 2019 Nov; 7(1):315. PubMed ID: 31753002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy after CAR T therapy.
    Sdrimas K; Diaz-Paez M; Camargo JF; Lekakis LJ
    Int J Hematol; 2020 Jul; 112(1):118-121. PubMed ID: 32125605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.